Allogene Therapeutics, Inc. ALLO

Updated: 10 Aug 2026

NASDAQ | Biotech | Biotechnology and cell therapy

No signal published yet

We already track Allogene Therapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Allogene Therapeutics free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Biotechnology and cell therapy
We're already tracking Allogene Therapeutics, Inc. — here are the latest events we've registered

Recent News

  • In July 2026, Allogene Therapeutics received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for its cema-cel candidate as a first-line consolidation therapy for large B-cell lymphoma. The designation was supported by positive interim data from the Phase 2 ALPHA3 trial demonstrating significant minimal residual disease clearance. Additionally, the company announced it will report its second quarter 2026 financial results on August 12, 2026.

What Firelda Watch includes for Allogene Therapeutics, Inc.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Allogene Therapeutics, Inc. will be delivered in the same format.

Sample analyses in the same sector

Sample full analysis — same format your watchlist gets

Hansa Biopharma AB (publ)
HNSA
HOLD
Bioarctic
BIOA B
BUY
Sprint Bioscience AB (publ)
SPRINT
NEUTRAL
Xbrane Biopharma AB (publ)
XBRANE
HOLD
SynAct Pharma AB
SYNACT
HOLD

Biotech

More companies in this sector

Want to follow Allogene Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Allogene Therapeutics free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Allogene Therapeutics, Inc. ALLO
Allogene Therapeutics — follow and we'll monitor it
Follow Allogene Therapeutics free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.